In 2006, the creation of sofie launched the aspiration of having a multifaceted approach to expand the reach of pet products for patients with advanced imaging needs This was further realized in 2017 with the addition of a radiopharmacy network with global distribution capabilities. Our team works alongside our pharma and academic partners to revolutionize clinical diagnostics and therapeutics to better understand and treat the biology of disease. Our product lines include fdg, pylarify, neuraceq, and other clinical trial products. We are currently performing data analysis and behind the scenes planning for phase 3 is well underway. Another defining moment for sofie biosciences
The first site, a collaboration with helios clinical research and radnet, has been activated and is ready to enroll patients. With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value theranostic intellectual property, sofie is poised to deliver on the promise of radiopharmaceuticals.
OPEN
